Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531
Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular Dystrophy (DMD), WVE-N531,…
News
Acumen concludes enrolment in Phase II trial of sabirnetug for Alzheimer’s
J&J’s NSCLC combo projected to extend survival by one year over Tagrisso
IGC Pharma posts promising interim data for Alzheimer’s therapy
Epicrispr secures $68m for facioscapulohumeral muscular dystrophy therapy trial
KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial
Axsome’s Sunosi succeeds in Phase III ADHD trial
Cassava ends simufilam Alzheimer’s programme after second Phase III failure
